velaglucerase alfa
HGT-GCB-068
Phase 2 mab completed
Quick answer
velaglucerase alfa for Gaucher Disease, Type 3 is a Phase 2 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Gaucher Disease, Type 3
- Phase
- Phase 2
- Modality
- mab
- Status
- completed